BAJAJ BROKING
Dr Reddy’s Laboratories announces the voluntary recall of six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg in the US due to powder discolouration, leading to decreased potency. Elevated Phenylalaninemia (Phe) levels pose risks of permanent neurocognitive deficits. The company urges consumers to contact physicians and return affected lots promptly.
Dr Reddy’s Laboratories Ltd has initiated a voluntary recall of six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg in the U.S. This recall comes as a result of powder discolouration observed in some packets, leading to decreased potency of the medication.
The reduced efficacy of the product poses a risk of elevated Phenylalaninemia (Phe) levels in patients. Chronic elevation of Phe levels, particularly in infants and children, is associated with permanent neurocognitive deficits such as intellectual disability, developmental delay, and seizures.
Moreover, elevated Phe levels during pregnancy, especially in early gestation, may lead to complications such as microcephaly and congenital heart disease.
Dr Reddy’s Laboratories Inc., the US-based subsidiary, has not received any adverse event reports related to this recall. However, consumers are urged to examine their inventory of the affected product and quarantine any recalled lots immediately.
Additional Read: Share Market News
The company advises consumers to consult their physician before discontinuing the use of the medication. Additionally, consumers are instructed to return the recalled product to their place of purchase.
The recall underscores the importance of quality control in pharmaceutical products to ensure the safety and efficacy of medications for patients.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Ashoka Buildcon Wins ₹312 Crore Substation Contract in Maharashtra
04 Nov, 2024 | 2 Min. read
NCC Secures Orders Worth ₹3,496 Crore in October 2024
04 Nov, 2024 | 2 Min. read
Deposit Growth Surpasses Credit Growth in the Banking Sector
04 Nov, 2024 | 2 Min. read
FPIs Withdraw Record ₹94,000 Crore from Indian Equities
04 Nov, 2024 | 2 Min. read
Commodities Market Today
04 Nov, 2024 | 1 Min. read
Share Market Today | Gift Nifty Signals Flat Opening For Indian Markets Today
04 Nov, 2024 | 4 Min. read
Gold Rate Today | Gold Prices Rise In Asia Amid U.S. Election Uncertainty
04 Nov, 2024 | 2 Min. read
Exide Industries Q2 Results FY24-25
04 Nov, 2024 | 3 Min. read
Market Crash: Why Sensex & Nifty Plunged Over 1.7% Today | Key Drivers
04 Nov, 2024 | 4 Min. read
Oil India Q2 Results FY24-25 Preview | Estimate
04 Nov, 2024 | 1 Min. read
IRCTC Q2 Results FY24-25 Preview | Estimat
04 Nov, 2024 | 1 Min. read
Titan Q2 Results FY’24-25 Estimates
04 Nov, 2024 | 1 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading